ABBV News

R40 coverage and dated third-party headlines for AbbVie Inc. (ABBV).

R40

R40 Coverage

News Jul 31, 2026

AbbVie Q2 2026: Skyrizi and Rinvoq Keep Compounding — Stock Falls on a Narrow EPS Miss

AbbVie beat revenue estimates as Skyrizi and Rinvoq grew over 24% each, but adjusted EPS missed by 6 cents and full-year guidance came down, sending shares down nearly 5%. We break down the immunology growth story against the near-term guidance drag.

R40

External

February 2026

News Feb 4, 2026

AbbVie Posts Double Beat for Q4

Q4 EPS $2.71 vs $2.65 est, revenue $16.62B vs $16.42B est; FY26 EPS guidance $14.37-$14.57 vs $14.24 est, signaling robust earnings growth.

Investing.com

News Feb 2, 2026

AbbVie All In on Obesity

AbbVie signals heavy obesity focus without explicit statement; expected to compete with Novo Nordisk, Merck, Bristol-Myers Squibb, emphasizing efficacy over oral vs. subcutaneous.

Fierce Pharma

External

January 2026

News Jan 29, 2026

AbbVie at JPM is All In on Obesity

AbbVie expresses enthusiasm for phase 1-2 obesity assets; anticipates big showdown with competitors like Novo Nordisk, Merck, and Lilly in weeks, not months.

BioSpace

News Jan 28, 2026

Biopharma Sentiment Just Snapped Higher

Biopharma sentiment surged with BPSI index jumping 78 to 90; aligns with public market price action and deal flow, expecting continued M&A and IPO activity into summer.

@BowTiedBiotech on X